← Back to Search

Monoclonal Antibodies

MEDI3506 for Asthma (FRONTIER-3 Trial)

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pharmacokinetic (pk) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24

Summary

This trial is testing a new medication called MEDI3506 to help adults with moderate to severe asthma that isn't well-controlled by their current treatments. The study will compare two different doses of MEDI3506. The goal is to see if MEDI3506 can better manage asthma symptoms by targeting specific pathways in the body.

Eligible Conditions
  • Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pharmacokinetic (pk) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and pharmacokinetic (pk) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic
Secondary study objectives
Asthma CompEx Annualised Event Rate
Change From Baseline to Week 16 in St George's Respiratory Questionnaire (SGRQ) Domain and Total Scores
Change From Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score
+8 more
Other study objectives
Change From Baseline to Week 16 in Pre-BD FEV1 as Measured in the Study Clinic: Analysis Per Number of Exacerbations in Last 12 Months
Eosinophil Count

Side effects data

From 2023 Phase 2 trial • 609 Patients • NCT04170543
6%
Hyperkalaemia
5%
Hypertension
4%
Oedema peripheral
3%
Diarrhoea
3%
Covid-19
3%
Arthralgia
2%
Urinary tract infection
2%
Vomiting
1%
Herpes zoster
1%
Diabetes mellitus
1%
Type 2 diabetes mellitus
1%
Dry eye
1%
Gout
1%
Pneumonia pseudomonal
1%
Anaemia
1%
Urticaria
1%
Vertigo
1%
Rash
1%
Abdominal pain
1%
Gastritis
1%
Rotator cuff syndrome
1%
Headache
1%
Sinusitis
1%
Haematuria
1%
Arthritis
1%
Platelet count increased
1%
Hypokalaemia
1%
Swelling face
1%
Seasonal allergy
1%
Abdominal distension
1%
Pulse absent
1%
Dysuria
1%
Orthostatic hypotension
1%
Abdominal discomfort
1%
Angina pectoris
1%
Coagulation test abnormal
1%
Fatigue
1%
Acute myocardial infarction
1%
Sars-cov-2 test positive
1%
Pneumonia
1%
Tooth infection
1%
Haemorrhagic stroke
1%
Acute kidney injury
1%
Hypervolaemia
1%
Dizziness
1%
Constipation
1%
Hypoglycaemia
1%
Left ventricular dysfunction
1%
Muscle spasms
1%
Abdominal pain upper
1%
Injection site pruritus
1%
Nausea
1%
Periarthritis
1%
Limb injury
1%
Hyperuricaemia
1%
Musculoskeletal chest pain
1%
Cellulitis
1%
Chronic kidney disease
1%
Bacteriuria
1%
Nasopharyngitis
1%
Fall
1%
C-reactive protein increased
1%
Back pain
1%
Cerebral haemorrhage
1%
Penile size reduced
1%
Blood creatinine increased
1%
Pain in extremity
1%
Skin ulcer
1%
Vision blurred
1%
Cataract
1%
Colitis
1%
Hypotension
1%
Osteomyelitis
1%
Lumbar spinal stenosis
1%
Pruritus
1%
Toothache
1%
Epicondylitis
1%
Ligament sprain
1%
Glycosylated haemoglobin increased
1%
Hypertensive urgency
1%
Influenza
1%
Blood pressure decreased
1%
Blood pressure increased
1%
Dysgeusia
1%
Prostate cancer recurrent
1%
Epistaxis
1%
Erythema
1%
Cholelithiasis
1%
Occult blood positive
1%
Dyspnoea
1%
Lymphopenia
1%
Pyrexia
1%
Covid-19 pneumonia
1%
Cerebrovascular accident
1%
Gastroenteritis
1%
Immunisation reaction
1%
Nail injury
1%
Traumatic haematoma
1%
Hypoglycaemia unawareness
1%
Neck pain
1%
Nephrolithiasis
1%
Renal impairment
100%
80%
60%
40%
20%
0%
Study treatment Arm
MEDI3506 300 mg
MEDI3506 120 mg
MEDI3506 30 mg
MEDI3506 60 mg
Placebo

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: MEDI3506 Dose 2Experimental Treatment1 Intervention
Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
Group II: MEDI3506 Dose 1Experimental Treatment1 Intervention
Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
Group III: PlaceboPlacebo Group1 Intervention
Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI3506
2021
Completed Phase 2
~1270

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,388 Previous Clinical Trials
289,109,573 Total Patients Enrolled
347 Trials studying Asthma
661,219 Patients Enrolled for Asthma
~49 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top